Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2001
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxelD Crivellari, O Pagani, A Veronesi, et al.
The Journal of Heredity|November 1, 1993
Molecular genetic and morphological analyses of the African wild dog (Lycaon pictus)D J Girman, P W Kat, M G Mills, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)R Morant, J Bernhard, R Maibach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II studyO Pagani, C Sessa, F Nolè, et al.
Oncogene|December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpressionS Vonlanthen, J Heighway, M P Tschan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2005
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicityM M Borner, J Bernhard, D Dietrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancerO Pagani, C Sessa, G Martinelli, et al.
British Journal of Cancer|April 1, 2004
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trialR Morant, J Bernhard, D Dietrich, et al.
British Journal of Cancer|March 10, 2005
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II studyE Van Cutsem, L Dirix, J-L Van Laethem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)A D Roth, R Maibach, G Martinelli, et al.
Pageof 8